14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBO vs PLRZ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Polyrizon Ltd. (PLRZ) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas PLRZ carries 31.6/100 (SELL) at $10.89 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and PLRZ (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile PLRZ is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs PLRZ. Trailing 12-month operating profitability (IBO -12621.0% vs PLRZ 0.0%) and valuation multiples (IBO N/M vs PLRZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $27.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IBO vs PLRZ Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Polyrizon Ltd. (PLRZ) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas PLRZ carries 31.6/100 (SELL) at $10.89 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and PLRZ (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile PLRZ is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with PLRZ at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus N/A for PLRZ. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLRZ.
IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas PLRZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus PLRZ (-21.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, PLRZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 88% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.